In conclusion, we have identified epigenetic alterations as a novel pathomechanism in XLMTM, and found that modification of the epigenome via HDAC inhibition is a promising therapeutic strategy for this fatal disorder. Here, HDAC9 is linked to X-linked myotubular myopathy.